BRITISH COLUMBIA, Canada, September 8 /PRNewswire/ --

InNexus Biotechnology Inc. (TSX: IXS.V; OTC Bulletin Board: IXSBF) (http://www.ixsbio.com), a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL(TM)) technology, announces Jeff Morhet, CEO and Chairman, to present during the Wall Street Analyst Forum at the University Club in New York City, Wednesday, September 10, 2008.

CEO and Chairman, Jeff Morhet will provide a company overview, including information about InNexus' unique business strategy, its DXL(TM) technology platform and upcoming company milestones. Investors, venture capitalists, company executives, scientists and other industry leaders will attend the conferences.

NEW YORK, September 8 /PRNewswire/ --

- New Local Kids Edition Launches in London on September 15

Young mums across the U.S. have depended upon DailyCandy Kids' free e-mail edition for the latest scoop on kids' products since 2002. Now, parents in the UK can stay in the know with the launch of DailyCandy Kids London.

DailyCandy, the free daily e-mail offering insider tips on what's hot, new, and undiscovered with 16 editions and more than 2.5 million subscriptions across the U.K., the U.S. and the rest of the world, has been delivering sweet tidbits to parents via its national Kids edition since 2002.

ROME, September 8 /PRNewswire/ --

- For European Medical Media Only

ROME, September 8 /PRNewswire/ --

- For Presentation Times and Detailed Study Information Please Refer to Notes to Editors

RESEARCH TRIANGLE PARK, North Carolina, September 8 /PRNewswire/ --

- Grab your smartphone and reclaim your freedom with WalkingHotSpot - the anytime, anywhere internet connection

TapRoot Systems, Inc., a leading developer of software solutions for the smartphone market, today announced that its "always-with-you" WalkingHotSpot (TM) internet connectivity solution is available for all consumers to purchase directly from http://www.walkinghotspot.com.

ROUSSET, France, September 8 /PRNewswire/ --

- AT73C224 Sources 3V to 5V Supplies, Provides Four Regulated Power Supply Channels, Integrates Real Time Clock and Two Wire Interface

Atmel(R) Corporation (Nasdaq: ATML) announced today the release of its AT73C224 Analog Companion Power Management Unit designed for a wide range of applications based on 32-bit MCUs. The AT73C224 supplies the required voltages and currents to the main sections of generic 32-bit MCU-based applications including MCU core, memory, I/O, USB host and interfaces.

TUCSON, Arizona, September 8 /PRNewswire/ --

- PicoGuard XP(TM) and PicoGuard XS(TM) Products for High Speed Serial Interfaces to be Highlighted

MUMBAI, India and BURLINGAME, California, September 8 /PRNewswire/ --

- Member of the $62.5 Billion Tata Group Invests $11.5 Million in Award-Winning CDN Company

Tata Communications, a leading provider of a new world of communications, and BitGravity, Inc., a next-generation Content Delivery Network (CDN) for interactive broadcasting, announced today the worldwide launch of Tata Communications' CDN service powered by BitGravity. With more than 300 points of presence worldwide, Tata Communications now offers the first truly global CDN service on a state of the art, single ASN global IP network throughout Europe, Asia, North America and India.

PARIS, September 8 /PRNewswire/ --

- The THIN, ROLE and LIVE-DE Studies Used Medical Databases or Medical Records to Compare the Benefits of Different Insulin Treatments in Thousands of People Living With Type 2 Diabetes

- Abstracts 1000, 1001 and 1004

Sanofi-aventis, a world leader in diabetes care, announced the results of three non-interventional studies presented at the 44th annual meeting of the European Association for the Study of Diabetes (EASD) in Rome, Italy (September 7 - 11, 2008), which demonstrated that treatment with LANTUS(R) (insulin glargine (rDNA origin) injection):

SAN DIEGO, California, September 8 /PRNewswire/ -- G.ho.st (the Global Hosted Operating SysTem pronounced "ghost"),which offers its Web-based G.ho.st Virtual Computer (VC) free of charge to every human being, today launched its brand new G.ho.st Mobile service at the prestigious DEMOfall conference in San Diego. The DEMO conferences are famous as launch pads for some of the world's hottest new technologies.

HIGH WYCOMBE, England, September 8 /PRNewswire/ --

- VELCADE Approved Across all Disease Stages for Broad Spectrum of Patients

Janssen-Cilag / Ortho Biotech, the biopharmaceutical division of Janssen-Cilag, today announced the European Commission's approval of VELCADE in combination with melphalan and prednisone for the treatment of patients with previously untreated multiple myeloma (MM) who are not eligible for high-dose chemotherapy with bone marrow transplant.

In more than 87 countries worldwide, VELCADE monotherapy had already been approved for the treatment of relapsed and / or refractory MM in patients who have received at least one prior therapy.